样式: 排序: IF: - GO 导出 标记为已读
-
An overview of point-of-care testing for infections in critically ill patients Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-02-27 Alena Moerman, Jan J. De Waele, Jerina Boelens
Molecular diagnostic systems for point-of-care (POC) testing are nowadays routinely used and are part of many labs. Although often intended for bedside use outside of the microbiology lab, there is...
-
The diagnosis of central nervous system infections in resource-limited settings and the use of novel and molecular diagnostic platforms to improve diagnosis Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-02-19 James Milburn, Rachita Suresh, Ronan Doyle, Joseph N Jarvis
Central nervous system infections (CNSI) disproportionately affect individuals in low-resource settings where diagnosis is challenging; large proportions of patients never receive a confirmed micro...
-
Detection of lung cancer and stages via breath analysis using a self-made electronic nose device Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-02-19 Binson V A, Philip Mathew, Sania Thomas, Luke Mathew
Breathomics is an emerging area focusing on monitoring and diagnosing pulmonary diseases, especially lung cancer. This research aims to employ metabolomic methods to create a breathprint in human-e...
-
Point-of-care urine tenofovir monitoring of adherence to drive interventions for HIV treatment and prevention Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-02-14 Matthew Spinelli, Monica Gandhi
Although effective antiretroviral and pre-exposure prophylaxis/PrEP regimens are available globally, adherence challenges persist. Objective measures of adherence can both measure adherence accurat...
-
Fast detection of bacterial gut pathogens on miniaturized devices: an overview Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-02-13 Gratiela Gradisteanu Pircalabioru, Mina Raileanu, Mihai Viorel Dionisie, Irina-Oana Lixandru-Petre, Ciprian Iliescu
Gut microbes pose challenges like colon inflammation, deadly diarrhea, antimicrobial resistance dissemination, and chronic disease onset. Development of early, rapid and specific diagnosis tools is...
-
From biochemical markers to molecular endotypes of osteoarthritis: a review on validated biomarkers Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-02-14 Monica T. Hannani, Christian S. Thudium, Morten A. Karsdal, Christoph Ladel, Ali Mobasheri, Melanie Uebelhoer, Jonathan Larkin, Jaume Bacardit, André Struglics, Anne-Christine Bay-Jensen
Osteoarthritis (OA) affects over 500 million people worldwide. OA patients are symptomatically treated, and current therapies exhibit marginal efficacy and frequently carry safety-risks associated ...
-
The impact of companion diagnostic testing on medical decision making and IVD regulations Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-02-12 Jan Trøst Jørgensen
Published in Expert Review of Molecular Diagnostics (Ahead of Print, 2024)
-
Polymerase Spiral Reaction (PSR) as a point-of-care diagnostic assay: A systematic review Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-02-09 Rashi Dixit, Naveen Kumar Kodali, Manisha Biswal, John Antony Jude Prakash, Natarajan Gopalan, Padma Das, Sujit Kumar Behera
The current systematic review aimed to collect and analyze the comprehensive evidence regarding Polymerase Spiral Reaction (PSR) and to estimate its diagnostic performance and usefulness as a point...
-
Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-02-09 Gabriele Roccuzzo, Eleonora Bongiovanni, Luca Tonella, Valentina Pala, Sara Marchisio, Alessia Ricci, Rebecca Senetta, Luca Bertero, Simone Ribero, Enrico Berrino, Caterina Marchiò, Anna Sapino, Pietro Quaglino, Paola Cassoni
Over the past two years, the scientific community has witnessed an exponential growth in research focused on identifying prognostic biomarkers for melanoma, both in pre-clinical and clinical settin...
-
Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-02-05 Gracia Maria Vargas, Neha Shafique, Xiaowei Xu, Giorgos Karakousis
Tumor-infiltrating lymphocytes (TILs) have been investigated as prognostic factors in melanoma. Recent advancements in assessing the tumor microenvironment in the setting of more widespread use of ...
-
The game changer: UCH-L1 and GFAP-based blood test as the first marketed in vitro diagnostic test for mild traumatic brain injury Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-01-31 Firas Kobeissy, Rawad Daniel Arja, Jennifer C. Munoz, Deborah A. Shear, Janice Gilsdorf, Jiepei Zhu, Hamad Yadikar, William Haskins, J. Adrian Tyndall, Kevin K. Wang
Major organ-based in vitro diagnostic (IVD) tests like ALT/AST for the liver and cardiac troponins for the heart are established, but an approved IVD blood test for the brain has been missing, high...
-
Multi-omics and single-cell sequencing analyses reveal the potential significance of circadian pathways in cancer therapy Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-01-30 Hao Lai, Xiaoyun Xiang, Xingqing Long, Zuyuan Chen, Yanling Liu, Xiaoliang Huang
Circadian rhythm disturbance is an independent risk factor for cancer. However, few studies have been reported on circadian rhythm related genes (CRGs) in cancer, so it is important to further expl...
-
SOWAHB polymorphisms affect thyroid cancer risk in the Chinese Han population Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-01-23 Man Zhang, Jing Liang, Junhui Han, Wenjing Zhang, Panpan Wan, Leteng Yang, Xufeng Zang, Wanli Ren, Ling Zhang, Hao Dai, Yue Wu, Tianbo Jin
This study aimed to detect the correlation between SOWAHB polymorphisms and Thyroid cancer (TC) risk in the Chinese Han population.We genotyped SOWAHB variants in 510 TC patients and 509 controls u...
-
Optimization of time interval for the measurement of plasma lipids for cardiovascular disease risk assessment Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-01-22 Maureen Sampson, Anna Wolska, Rafael Zubiran, Justine Cole, Marcelo Amar, Alan T. Remaley
Lipid testing for atherosclerotic cardiovascular disease (ASCVD) risk is often performed every 4–6 years, but we hypothesized that the optimum time interval may vary depending on baseline risk.Usin...
-
Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the IdyllaTM platform: a real-world two-center experience in Greece Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-01-11 Kleita Michaelidou, Ioannis Karniadakis, Varvara Pantelaion, Chara Koutoulaki, Eleni Boukla, Konstantinos Folinas, Pantelis Dimaras, Maria A Papadaki, Anastasios V Koutsopoulos, Dimitrios Mavroudis, Christine Vourlakou, Konstantinos Mavridis, Sofia Agelaki
Limited information exists on epidermal growth factor receptor (EGFR) molecular epidemiology in Greece. Next-generation sequencing (NGS) is the recommended method for EGFR genotyping in NSCLC. The ...
-
Molecular biomarkers of diffuse axonal injury: recent advances and future perspectives Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-01-11 Youyou Zhang, Zhaoyang Li, Hui Wang, Zhiyong Pei, Shuquan Zhao
Diffuse axonal injury (DAI), with high mortality and morbidity both in children and adults, is one of the most severe pathological consequences of traumatic brain injury. Currently, clinical diagno...
-
Utilization and outcomes of the 21-gene recurrence score in de novo metastatic breast cancer Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-01-05 Shi-Ping Yang, Ke Liu, Yang Li, Guan-Qiao Li, Jia-Yi Li, Yu-Yi Lin, San-Gang Wu
Limited data exist regarding the utility and validity of the 21-gene recurrence score (RS) in patients with de novo metastatic breast cancer (dnMBC). This study aimed to investigate the practice pa...
-
We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what? Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2024-01-04 Jason Grebely, Susan Matthews, Louise M. Causer, Jordan J. Feld, Philip Cunningham, Gregory J. Dore, Tanya L. Applegate
Progress toward hepatitis C virus (HCV) elimination is impeded by low testing and treatment due to the current diagnostic pathway requiring multiple visits leading to loss to follow-up. Point-of-ca...
-
Advancements in protein glycosylation biomarkers for ovarian cancer through mass spectrometry-based approaches Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-19 Jua Lee, Ji Eun Park, Daum Lee, Nari Seo, Hyun Joo An
Ovarian cancer, characterized by metastasis and reduced 5-year survival rates, stands as a substantial factor in the mortality of gynecological malignancies worldwide. The challenge of delayed diag...
-
Molecular and epigenetic mechanisms governing ocular surface squamous neoplasia: opportunities for diagnostics Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-22 Bharat Gurnani, Kirandeep Kaur
Ocular surface squamous neoplasia (OSSN) is the most common ocular malignancy; the pathophysiology is influenced by molecular, genetic, and epigenetic mechanisms. The incidence of OSSN is associate...
-
The challenges and potential in developing microRNA associated with regeneration as biomarkers to improve prognostication for liver failure syndromes and hepatocellular carcinoma Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-19 Oliver D Tavabie, Siamak Salehi, Varuna R Aluvihare
Determining the need for liver transplantation remains critical in the management of hepatocellular carcinoma (HCC) and liver failure syndromes (including acute liver failure and decompensated cirr...
-
Progress in the field of noninvasive diagnostics for colorectal cancer: a systematic review for the accuracy of blood-based biomarkers for detection of advanced pre-cancerous lesions Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Rishabh Goyal, Molla M Wassie, Jean M Winter, Timothy JH Lathlean, Graeme P Young, Erin L Symonds
Early detection of pre-cancerous adenomas through screening can reduce colorectal cancer (CRC) incidence. Fecal immunochemical tests are commonly used, but have limited sensitivity for pre-cancerou...
-
Validating blood tests as a possible routine diagnostic assay of Alzheimer’s disease Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Eleftheria Kodosaki, Henrik Zetterberg, Amanda Heslegrave
In recent years, exciting developments in disease modifying treatments for Alzheimer’s disease (AD) have made accurate and timely diagnosis of this disease a priority. Blood biomarkers (BBMs) for a...
-
Diagnostics in skeletal muscle channelopathies Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Alex Vicino, Raffaella Brugnoni, Lorenzo Maggi
Skeletal muscle channelopathies (SMCs) are a heterogenous group of disorders, caused by mutations in skeletal ion channels leading to abnormal muscle excitability, resulting in either delayed muscl...
-
Molecular diagnostic criteria of myeloproliferative neoplasms Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Claire Andrews, Eibhlin Conneally, Stephen E. Langabeer
Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal hematopoietic stem cell neoplasms characterized by the driver mutations JAK2, CALR, and MPL. These mutations cause constitutiv...
-
A charming molecular profile in the wrong tissue: the pathologist in the era of molecular diagnostics in the gastrointestinal tract Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Paola Parente, Federica Grillo, Alessandro Vanoli, Luca Mastracci, Matteo Fassan
Published in Expert Review of Molecular Diagnostics (Vol. 23, No. 12, 2023)
-
Synovial biopsies for molecular definition of rheumatoid arthritis and treatment response phenotyping: where can we improve? Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Francesco Salvatore Iaquinta, Felice Rivellese, Costantino Pitzalis
The extensive knowledge gained in the cellular and molecular mechanisms underlying Rheumatoid Arthritis (RA) pathogenesis has led to therapeutic advances. However, up to 10–20% of patients fail to ...
-
A case for non-coding RNA as a suitable biomarker of amyotrophic lateral sclerosis Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Greig Joilin, Majid Hafezparast
Published in Expert Review of Molecular Diagnostics (Vol. 23, No. 12, 2023)
-
Identification of a novel epigenetic marker for typical and mosaic presentations of Fragile X syndrome Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Camilla Pereira da Silva, Diego Camuzi, Adriana Helena de Oliveira Reis, Andressa Pereira Gonçalves, Jussara Mendonça dos Santos, Filipe Brum Machado, Enrique Medina-Acosta, Sheila Coelho Soares-Lima, Cíntia Barros Santos-Rebouças
Fragile X syndrome (FXS) is primarily due to CGG repeat expansions in the FMR1 gene. FMR1 alleles are classified as normal (N), intermediate (I), premutation (PM), and full mutation (FM). FXS patie...
-
Cross-sectional risk models using quantitative fecal hemoglobin in colorectal cancer screening: a systematic review Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Tim Kortlever, Willemijn de Klaver, Manon van der Vlugt, Gerrit Meijer, Evelien Dekker, Patrick Bossuyt
Fecal Immunochemical Testing (FIT) is a central tool in colorectal cancer (CRC) screening. To improve the selection of individuals for colonoscopy, risk models combining FIT with additional CRC ris...
-
MicroRnas in preeclampsia Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Zacharias Fasoulakis, Aggeliki Kolialexi, Danai Mavreli, Marianna Theodora
Published in Expert Review of Molecular Diagnostics (Vol. 23, No. 12, 2023)
-
The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Ryouichi Tsunedomi, Yoshitaro Shindo, Masao Nakajima, Kiyoshi Yoshimura, Hiroaki Nagano
Pancreatic cancer (PC) has an extremely poor prognosis, even with surgical resection and triplet chemotherapy treatment. Cancer immunotherapy has been recently approved for tumor-agnostic treatment...
-
Current and emerging biomarkers for ulcerative colitis Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Jan K. Nowak, Rahul Kalla, Jack Satsangi
Ulcerative colitis (UC) is a chronic illness requiring lifelong management that could be enhanced by personalizing care using biomarkers.The main biomarker discovery modalities are reviewed, highli...
-
Challenges associated with using extracellular vesicles as biomarkers in neurodegenerative disease Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Yvonne Couch
The hunt for new biomarkers – for the diagnosis of subcategories of disease, or for the monitoring of the efficacy of novel therapeutics – is an increasingly relevant challenge in the current era o...
-
Usefulness of an RNA extraction-free test for the multiplexed detection of ALK, ROS1, and RET Gene Fusions in Real Life FFPE Specimens of Non-Small Cell Lung Cancers Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Francesca Damiola, Laurent Alberti, Audrey Mansuet-Lupo, Diane Damotte, Véronique Hofman, Lucie Tixier, Frédérique Penault-Llorca, Isabelle Rouquette, Jean Michel Vignaud, Aurélie Cazes, Fabien Forest, Hugues Begueret, Laure Gibault, Cécile Badoual, Anne Cayre, Estelle Taranchon-Clermont, Adeline Duc, Anne Mc Leer, Sylvie Lantuejoul
ALK, ROS1 and RET rearrangements occur, respectively, in 5%, 2%, and 1% non-small cell lung cancers (NSCLC). ALK and ROS1 fusion proteins detection by immunohistochemistry (IHC) has been validated ...
-
A systematic review and meta-analysis on the relative and attributable risk of Helicobacter pylori infection and cardia and non-cardia gastric cancer Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Jianhua Gu, Feifan He, Gary M Clifford, Minjuan Li, Zhiyuan Fan, Xinqing Li, Shaoming Wang, Wenqiang Wei
This study aimed to update the association between Helicobacter pylori (H. pylori) infection and gastric cancer (GC).We searched PubMed, Embase, and Cochrane Library from 1990 to December 2021 to i...
-
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer’s disease Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Lorenzo Gaetani, Davide Chiasserini, Federico Paolini Paoletti, Giovanni Bellomo, Lucilla Parnetti
Cerebrospinal fluid (CSF) biomarkers represent a well-established tool for diagnosing Alzheimer’s disease (AD), independently from the clinical stage, by reflecting the presence of brain amyloidosi...
-
Functional proteomic analysis, a missing piece for understanding clonal evolution and cooperation in the tissue microecology Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Mariaelena Pierobon, Emanuel F. Petricoin
Published in Expert Review of Molecular Diagnostics (Vol. 23, No. 12, 2023)
-
LncRNA NR2F1-AS1 as a potential biomarker for prognosis in cancer patients: meta and bioinformatics analysis Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Lu Tang, Qing-Mei Liu, Shuang Zhang, Jun Zhou
Previous studies have shown that the differential expression of lncRNA NR2F1-AS1 is closely related to the prognosis of cancer, but the conclusion is still controversial. Therefore, we conducted a ...
-
Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Matteo Ferro, Bernardo Rocco, Martina Maggi, Giuseppe Lucarelli, Ugo Giovanni Falagario, Francesco Del Giudice, Felice Crocetto, Biagio Barone, Evelina La Civita, Francesco Lasorsa, Antonio Brescia, Michele Catellani, Gian Maria Busetto, Octavian Sabin Tataru, Daniela Terracciano
New potential biomarkers to pre-intervention identification of a clinically significant prostate cancer (csPCa) will prevent overdiagnosis and overtreatment and limit quality of life impairment of ...
-
Clinical application of circulating tumor DNA in metastatic cancers Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Negin Raei, Reza Safaralizadeh, Saeid Latifi-Navid
Advances in genomics have facilitated the application of cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) in phase II and phase III clinical trials. The various mutations of cfDNA/ctDNA have...
-
An update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-15 Jeffrey D. Jenks, P. Lewis White, Sarah E. Kidd, Tyler Goshia, Stephanie I. Fraley, Martin Hoenigl, George R. Thompson III
Invasive fungal infections cause millions of infections annually, but diagnosis remains challenging. There is an increased need for low-cost, easy to use, highly sensitive and specific molecular as...
-
How our molecular understanding of the pathogenesis of Mycobacterium ulcerans infection can improve diagnosis of Buruli ulcer Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-12-14 Gerd Pluschke, Louisa Warryn
Published in Expert Review of Molecular Diagnostics (Vol. 24, No. 1-2, 2024)
-
Molecular imaging of PARP in cancer: state-of-the-art Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-11-27 Luca Filippi, Luca Urso, Viviana Frantellizzi, Katia Marzo, Maria Cristina Marzola, Orazio Schillaci, Laura Evangelista
Poly-ADP-ribose-polymerase inhibitors (PARPi), which exploit the processes of so-called ‘synthetic lethality,’ have been successfully implemented in oncological practice. However, not all patients ...
-
A fast-track to fungal diagnosis: the potential of molecular diagnostics for fungi at the point of care Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-11-22 Paul Trubin, Marwan Azar
Published in Expert Review of Molecular Diagnostics (Just accepted, 2023)
-
Lessons from the pandemic: new best practices in selecting molecular diagnostics for point-of-care testing of infectious diseases in sub-saharan Africa Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-10-31 Mamadu Baldeh, Flavia K. Bawa, Faiza U. Bawah, Martin Chamai, Francis Dzabeng, Waleed M.A. Jebreel, Jean-Bertin B. Kabuya, Shola K. Molemodile Dele-Olowu, Erick Odoyo, Dimbintsoa Rakotomalala Robinson, Aubrey J. Cunnington
Point-of-care molecular diagnostics offer solutions to the limited diagnostic availability and accessibility in resource-limited settings. During the COVID-19 pandemic, molecular diagnostics became...
-
Recent advance of next-generation sequencing in patients with lung cancer Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-10-24 Tianyu Qiu, Xinxin Zhi, Shengxiang Ren
Precision medicine based on the driver genes mutation status is the current systemic therapeutic paradigm in patients with lung cancer. Next-generation sequencing (NGS) has emerged as a powerful pl...
-
Implementing individualized quality control plans and managing risk at the point-of-care for molecular diagnostics Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-10-28 Erving T. Laryea, James H. Nichols
Faster turnaround times can lead to rapid patient treatment. Implementing a POC molecular COVID-19 test requires careful planning. In the POC setting, there are numerous operators and regular monit...
-
Salivette® Cortisol versus oropharyngeal swabbing for the detection of SARS-CoV-2 infection Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-10-24 Petra Moroni-Zentgraf, Christoph Keller, Christoph C. Eschenfelder, Hanns Walter Müller, Ralf Sigmund, David Galeana-Cadena, José Eduardo Márquez-García, Angélica Moncada-Morales, Joaquin A. Zúñiga
Detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by naso/oropharyngeal swabbing may expose health-care workers to the virus and is technically challenging. The Salivette® is a...
-
Retrospective analysis of persistent HyperCKemia with or without muscle weakness in a case series from Greece highlights vast heterogeneous DMD gene variants. Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-09-27 Kyriaki Kekou, Maria Svingou, Nikos Vogiatzakis, Evangelia Nitsa, Danai Veltra, Nikolaos M. Marinakis, Faidon-Nikolaos Tilemis, Maria Tzetis, Anastasios Mitrakos, Charalambia Tsaroucha, Nicoletta Selenti, Giorgos-Konstantinos Papadimas, Constantinos Papadopoulos, Joanne Traeger-Synodinos, Hanns Lochmuller, Christalena Sofocleous
Persistent hyperCKemia results from muscle dysfunction often attributed to genetic alterations of muscle related genes, such as the dystrophin gene (DMD). Retrospective assessment of findings from ...
-
Maintaining point of care testing capacity and pandemic preparedness in the post-COVID-19 era Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-09-19 Jennifer L. Rakeman-Cagno, David H. Persing, Michael J. Loeffelholz
Testing at the point of care (we also refer to the ‘point of need’), with rapid, actionable results reported to the patient and provider within hours can impact the individual as well as public hea...
-
Diagnostic accuracy of serum derived exosomes for hepatocellular carcinoma: a systematic review and meta-analysis Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-09-15 Amir Tiyuri, Shayeste Sadat Baghermanesh, Yasamin Davatgaran-Taghipour, Seyed Sadegh Eslami, Nasibeh Shaygan, Houman Parsaie, Mahmood Barati, Davod Jafari
Early and non-invasive detection of hepatocellular carcinoma (HCC), which is usually asymptomatic, can improve overall survival outcomes. The objective of this systematic review and meta-analysis w...
-
Biomarkers to guide immunomodulatory treatment: where do we stand? Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-09-10 Evdoxia Kyriazopoulou, Evangelos J Giamarellos-Bourboulis, Karolina Akinosoglou
ABSTRACT Introduction This review summarizes current progress in the development of biomarkers to guide immunotherapy in oncology, rheumatology and critical illness. Areas covered An extensive literature search was performed about biomarkers classifying patients’ immune responses to guide immunotherapy in oncology, rheumatology and critical illness. Surface markers, such as programmed death-ligand
-
Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-09-13 Jinghua Xia, Jiao Zhang, Yanlu Xiong, Jinbo Zhao, Yinxi Zhou, Tao Jiang, Jianfei Zhu
The advance of diagnostics and treatments has greatly improved the prognosis of non-small cell lung cancer (NSCLC) patients. However, relapse and metastasis are still common problems encountered by...
-
Serum Sema7A is increased in patients with acute aortic dissection Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-09-12 Xing Lyu, Xin Liu, Hui Gong, Yang Liu, Zhifang Zhou, Min Hu, Xiangyu Zhang
To observe the level of serum Sema7A in acute aortic dissection (AAD) and its diagnostic value for AAD.Patients with sudden chest pain including AAD, acute myocardial infarction (AMI) or pulmonary ...
-
Global polymorphism of Plasmodium falciparum histidine rich proteins 2/3 and impact on malaria rapid diagnostic test detection: a systematic review and meta-analysis Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-09-12 Loick P. Kojom Foko, Jahnvi Jakhan, Geetika Narang, Vineeta Singh
This review presents an overview of field findings on sequence variation of Plasmodium falciparum histidine-rich proteins 2/3 (PfHRP2/3) for which reference types (1–24) have been identified, and i...
-
External quality assessment for the molecular detection of microsatellite instability in China, 2021-2022 Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-09-12 Xiaoyu Fan, Qianming Bai, Chunli Shi, Yanqun Xiao, Xueliang Wang
Microsatellite instability (MSI) analysis of tumors informs Lynch syndrome testing, therapeutic choice, and prognosis. The status of MSI is mainly detected by polymerase chain reaction coupled with...
-
Point-of-care testing for viral-associated pulmonary aspergillosis Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-09-09 Robina Aerts, Brice Autier, Maximilian Gornicec, Juergen Prattes, Katrien Lagrou, Jean-Pierre Gangneux, Martin Hoenigl
ABSTRACT Introduction Over the last years, severe respiratory viral infections, particularly those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the influenza virus, have emerged as risk factor for viral-associated pulmonary aspergillosis (VAPA) among critically ill patients. Delays in diagnosis of VAPA are associated with increased mortality. Point-of-care-tests may play
-
Reprogramming of lipid metabolism in hepatocellular carcinoma resulting in downregulation of phosphatidylcholines used as potential markers for diagnosis and prediction Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-09-06 Kang Li, Wanting Shi, Yi Song, Lin Qin, Chaoran Zang, Tingting Mei, Ang Li, Qingkun Song, Yonghong Zhang
Aberrant methylation and metabolic perturbations may deepen our understanding of hepatocarcinogenesis and help identify novel biomarkers for diagnosing hepatocellular carcinoma (HCC). We aimed to d...
-
The diagnostic and prognostic value of tsRNAs in gastric cancers: a systematic review and meta-analysis Expert Rev. Mol. Diagn. (IF 5.1) Pub Date : 2023-09-06 Hua Gao, Qiankun Zhang, Weibing Wu, Jing Gu, Jia Li
Gastric cancer (GC) is one of the most common types of cancer worldwide. Recent studies have shown that tsRNAs play important roles in GC and that changes in the expression levels of tsRNAs can be ...